论文部分内容阅读
目的探讨前列腺增生症患者血清中前列腺特异性抗原水平与慢性前列腺炎的关系。方法128例门诊诊断为前列腺增生症的患者,其血清前列腺特异性抗原高于4.0ng/ml且合并慢性前列腺炎;所有患者口服塞来昔布,治疗随访6周;根据治疗后血清前列腺特异性抗原水平及前列腺穿刺活检结果分为三组,观察比较各组治疗前后血清前列腺特异性抗原的水平及前列腺癌诊断阳性率。结果仅治疗后血清前列腺特异性抗原低于4.0ng/ml的一组在治疗前后的水平变化有统计学意义,其余两组均无统计学意义;治疗后前列腺癌诊断阳性率明显高于治疗前。结论对血清前列腺特异性抗原高于4.0ng/ml且合并慢性前列腺炎的前列腺增生患者进行抗炎治疗,既可提高前列腺特异性抗原对前列癌早期诊断的特异性,又可使部分患者避免前列腺穿刺活检造成的痛苦和相关并发症。
Objective To investigate the relationship between the level of prostate-specific antigen in serum of patients with benign prostatic hyperplasia and chronic prostatitis. Methods A total of 128 outpatients with benign prostatic hyperplasia (BPH) were enrolled. Their serum PSA was higher than 4.0ng / ml and had chronic prostatitis. All patients were treated with celecoxib for 6 weeks. According to the serum PSA Antigen levels and prostatic biopsy results were divided into three groups, observed and compared before and after treatment serum prostate-specific antigen levels and the positive rate of prostate cancer diagnosis. Results The level of serum prostate-specific antigen in patients with serum PSA of less than 4.0ng / ml after treatment was statistically significant before and after treatment, and the other two groups had no statistical significance. The positive rate of prostate cancer after treatment was significantly higher than that before treatment . Conclusion Anti-inflammatory treatment of patients with benign prostatic hyperplasia with serum prostate-specific antigen higher than 4.0ng / ml and chronic prostatitis can not only improve the specificity of prostate-specific antigen in the early diagnosis of prostate cancer, but also can prevent some patients from prostate Prostate biopsy caused by the pain and related complications.